UNITED THERAPEUTICS Corp (UTHR) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, UNITED THERAPEUTICS Corp's filing signal continuing positive.

United Therapeutics Corporation is a public benefit corporation focused on developing novel pharmaceutical therapies and organ manufacturing technologies to address unmet medical needs in rare diseases. The company markets five treprostinil-based therapies (Tyvaso DPI, Nebulized Tyvaso, Remodulin, Orenitram) and one tadalafil-based therapy (Adcirca) for pulmonary hypertension (PAH) and related conditions in the United States, with some products also sold internationally. Additionally, it markets Unituxin for high-risk neuroblastoma. United Therapeutics is also pioneering xenotransplantation, regenerative medicine, and ex vivo lung perfusion technologies to expand the availability of transplantable organs, with key development-stage products including UKidney, UHeart, and UThymoKidney.

Primary revenue drivers are sales of its treprostinil-based therapies, particularly Tyvaso DPI and Nebulized Tyvaso, which accounted for 59% of total revenues in 2025. Other significant revenue contributors include Remodulin, Orenitram, Unituxin, and Adcirca.